Shimadzu Registers HPLC and LCMS Instruments as Class I Medical Devices with FDA
News Apr 01, 2014
In response to a growing need for analytical measurement in healthcare applications, Shimadzu Corporation, Japan, has registered several of the company’s high-performance liquid chromatographs (HPLC) and high-performance liquid chromatograph mass spectrometers (LCMS) as Class I medical devices with the Food and Drug Administration.
The use of analytical devices in medical screenings and disease prevention has been on the rise in recent years. Starting in July 2011, the FDA required manufacturers to register analytical instruments as Class I medical devices to ensure their accuracy and reliability when used in healthcare applications.
The following Shimadzu instruments have been registered as Class I medical devices:
• LC-20 CL and LC-30 CL HPLCs
• Single-quad LCMS-2020 CL
• Triple-quad LCMS-8030 CL, LCMS-8040 CL and LCMS-8050 CL
The registered instruments were designed in Shimadzu Corporation’s head office (Sanjo Works, Japan) and manufactured at Shimadzu USA Manufacturing (SUM) located in Canby, Ore. Both facilities obtained ISO 13485 certification, the globally recognized international quality management standard for medical equipment, in 2013. SUM is conducting manufacturing of the medical devices mentioned under the FDA regulation 21 CFR 820.
Arrow Poison Potential Male Birth ControlNews
Women have many options for oral contraceptives that are safe, effective and reversible, but despite decades of research, men have none. Now, scientists report a rat study that shows they finally have a good lead for a male birth control pill. It's based on ouabain, a plant extract that African warriors and hunters traditionally used as a heart-stopping poison on their arrows.READ MORE
Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule InhibitorsNews
A new original research article presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase, a promising target for developing anti-cancer drugs.READ MORE